

- **Full Name:** Thierry CONROY
 - **Current Position & Affiliation:** Professor of Oncology, Lorraine University. Medical oncologist, Institut de cancérologie de Lorraine, Nancy
 - **Country:** France
-

• Educational Background:

- 1982: Graduated as doctor of medicine
- 1982: Graduated as gastroenterologist
- 1983: Graduated as pulmonologist
- 1984: Master's degree in biology, section haematology
- 1984: Graduated as specialist in internal medicine
- 1986: Master's degree in biology, section oncology
- 1988: Master's degree in biology, section genetics
- 1990: Master in pharmacology: drugs' metabolism and clinical pharmacology
- 1993: Graduated as medical oncologist
- 1993: Full professor of oncology, Lorraine University, Nancy, France

• Professional Experience:

- Assistant Professor, Department of Haematology, Nancy University Hospital, 1982-1984
- Medical Oncology Specialist in the French Comprehensive Cancer Centers, 1990
- Chairman of the Group "GI tumors" of the French anticancer centers 2008-2010 (now UNICANCER GI, UCGI)
- Board member of the EORTC Gastrointestinal Group until 2012
- Member of the EORTC Quality of life group since 1993
- Coordinator of the French multicentric randomized trials PRODIGE 5-ACCORD 17, PRODIGE 4-ACCORD 11, PRODIGE 23, and PRODIGE 44 and international PRODIGE 24-CCTG PA6.
- Director of the Comprehensive Cancer Center "Institut de Cancérologie de Lorraine" in Nancy (2012-2022).
- Elected in 2019 as vice-president of UNICANCER

• Professional Organizations:

- Lorraine University, research unit APEMAC: "Chronic diseases, perceived health and adaptation process. Epidemiological and psychological approaches »
- Institut de cancérologie de Lorraine, Nancy
- UNICANCER
- PRODIGE intergroup for gastro-intestinal cancers research

• Main Scientific Publications (limited to 10 references):

1. Bascoul-Mollevi C, Gourgou S, Borg C, *et al.*
Neoadjuvant Chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-Related Quality of Life longitudinal analysis.
Eur J Cancer 2023;186:151-65.
2. Conroy T, Castan F, Lopez A, *et al.*
Five-Year Outcomes of FOLFIRINOX versus Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
JAMA Oncol 2022; 8:1571-8.
3. T Conroy, J-F Bosset, P-L Etienne, *et al.*
Neoadjuvant Chemotherapy with FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): a Multicentre, Randomised, open label, Phase 3 Study.
Lancet Oncol. 2021; 22: 702-15.
4. T Conroy, P Hammel, M Hebbar, *et al.*
FOLFIRINOX versus Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
N Engl J Med 2018; 379: 2395-406.
5. T Conroy, MP Galais, JL Raoul, *et al.*
Definitive chemoradiotherapy with FOLFOX versus fluorouracil/cisplatin in patients with oesophageal cancer: final results of a randomised, phase 2/3 intergroup trial (PRODIGE 5/ACCORD 11).
Lancet Oncol 2014; 15: 305-14.
6. S. Gourgou-Bourgade, C. Bascoul-Mollevi, F. Desseigne, *et al.*
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial.
J Clin Oncol 2013; 31: 23-9.
7. JP. Gérard, D. Azria, S. Gourgou-Bourgade, *et al.*
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer.
J Clin Oncol 2012; 30: 4558-65.
8. T.Conroy, F. Desseigne, M. Ychou, *et al.*
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer.
N Engl J Med 2011; 364: 1817-25.
9. JP. Gérard, D. Azria, S. Gourgou-Bourgade, *et al.*
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer. Results of the phase III trial ACCORD 12/0405-Prodige 2.
J Clin Oncol 2010; 28: 1638-44.
10. JP. Gérard, T. Conroy, F. Bonnetain *et al.*
Preoperative radiotherapy with or without concurrent Fluorouracil and leucovorin in T3-4 rectal cancers: results of the FFCD 9203.
J Clin Oncol 2006; 24: 4620-5.